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Abstract	
Multi-arm	multi-stage	trial	designs	can	bring	notable	gains	 in	efficiency	to	the	drug	
development	 process.	 However,	 for	 normally	 distributed	 endpoints,	 the	
determination	 of	 a	 design	 typically	 depends	 on	 the	 assumption	 that	 the	 patient	
variance	in	response	is	known.	In	practice,	this	will	not	usually	be	the	case.	To	allow	
for	 unknown	 variance,	 previous	 research	 explored	 the	 performance	 of	 𝑡 -test	
statistics,	coupled	with	a	quantile	substitution	procedure	for	modifying	the	stopping	
boundaries,	at	 controlling	 the	 familywise	error-rate	 to	 the	nominal	 level.	Here,	we	
discuss	 an	 alternative	 method	 based	 on	 Monte	 Carlo	 simulation	 that	 allows	 the	
group	size	and	stopping	boundaries	of	a	multi-arm	multi-stage	𝑡-test	to	be	optimised	
according	 to	 some	 nominated	 optimality	 criteria.	 We	 consider	 several	 examples,	
provide	 R	 code	 for	 general	 implementation,	 and	 show	 that	 our	 designs	 confer	 a	
familywise	 error-rate	 and	 power	 close	 to	 the	 desired	 level.	 Consequently,	 this	
methodology	will	provide	utility	in	future	multi-arm	multi-stage	trials.	
	
Keywords:	 Familywise	 error-rate;	 Group	 sequential;	 Interim	 analyses;	 Multi-arm	
multi-stage;	𝑡-statistic.	
	
1. Introduction	
	
With	the	cost	of	drug	development	 increasing,	study	designs	that	can	enhance	the	
efficiency	of	clinical	 research	are	of	great	 interest.	One	such	class	of	designs	 is	 the	
group	sequential	[1].	This	approach	exploits	the	fact	that	data	are	accumulated	over	
time:	 incorporating	 interim	 analyses	 at	 which	 the	 study	 may	 be	 stopped	 early,	
reducing	the	required	sample	size.	
	
Recently,	 this	 methodology	 was	 extended	 to	 allow	 multiple	 treatments	 to	 be	
compared	to	a	shared	control	[2].	These	multi-arm	multi-stage	(MAMS)	designs	can	
bring	sizeable	gains	in	efficiency	over	conducting	a	series	of	single-stage	two-armed	
trials	 [3].	 Unfortunately,	 a	 limitation	 of	 this	 methodology	 in	 the	 case	 of	 normally	
distributed	 outcome	 data	 is	 that	 designs	 are	 usually	 determined	 under	 the	
supposition	of	known	patient	variance	in	response.	Typically,	this	will	not	be	the	case	
at	 the	 design	 stage.	 Then,	 utilising	 test	 statistics	 that	 assume	 known	 variance	will	
result	 in	 operating	 characteristics	 that	 differ	 from	 their	 nominal	 level	 if	 the	 true	
variance	is	not	equal	to	the	specified	value.	
	
For	 two-armed	group	sequential	 trials,	 several	authors	have	suggested	methods	 to	
broach	 this	 problem.	 These	 include	 a	 recursive	 algorithm	 [4],	 and	 a	 quantile	
substitution	procedure	[1,5].	The	latter	approach	was	also	explored	for	MAMS	trials,	
and	demonstrated	 to	more	 accurately	 control	 the	 familywise	 error-rate	 (FWER)	 to	
the	desired	level,	at	a	small	cost	to	the	trial’s	power	[6].	
	
A	Monte	Carlo	based	procedure	was	also	proposed	for	two-armed	group	sequential	
trials	[7].	In	this	paper,	we	extend	it	to	MAMS	trials.	Explicitly,	we	describe	how	the	
stage-wise	group	size	and	stopping	boundaries	can	be	optimised.	Finally,	using	 the	
TAILoR	 trial	 [2]	 as	 a	 motivating	 example,	 we	 compare	 the	 performance	 of	 our	
method	to	several	other	approaches.	
	
2. Methods	
	
We	consider	a	MAMS	trial	with	𝐾 + 1	arms,	and	a	maximum	of	𝐽	stages.	Of	the	arms,	𝐾	(indexed	𝑘 = 1,… ,𝐾)	are	to	be	compared	to	a	single	control	arm	(indexed	𝑘 = 0).	
We	test	the	following	hypotheses	
	 𝐻!! ∶ 𝜃! = 𝜇! − 𝜇! ≤ 0,    𝐻!! ∶  𝜃! = 𝜇! − 𝜇! > 0,     𝑘 = 1,… ,𝐾.	
	
Here,	𝜇!	is	the	mean	response	of	patients	allocated	to	arm	𝑘 = 0,… ,𝐾.	We	assume	
that	in	each	stage,	𝑛	patients	are	allocated	to	each	arm	present	in	the	trial.	To	allow	
for	 the	 early	 dropping	 of	 arms,	 we	 denote	 by	𝑛!" 	the	 actual	 number	 of	 patients	
allocated	 to	 arm	𝑘 = 0,… ,𝐾	in	 stage	𝑗 = 1,… , 𝐽.	 Thus,	𝑛!" ∈ 0,𝑛 .	 Designs	 with	
unequal	allocation,	or	with	two-sided	null	hypotheses	could	be	treated	similarly.		
	
Denoting	by	𝑋!"# 	the	response	of	the	𝑖th	patient,	in	treatment	arm	𝑘,	 in	stage	𝑗,	we	
assume	 that	 the	 𝑋!"# 	are	 independent	 and	 distributed	 as	 𝑋!"#  ~ 𝑁 𝜇! ,𝜎! .	
Extending	[7],	set	
	 𝑁!" = 𝑛!"!!!! ,                                                   	𝑋!" = 1𝑁!" 𝑋!"#!!!!
!
!!! ,                                    	                    𝜎!! = 1𝑁!"!!!! − 𝐾 + 1 𝑋!"# − 𝑋!" !!!!!
!
!!!
!
!!! ,	
	
where	𝑋!"# = 0	∀𝑖	if	𝑛!" = 0.	 At	 interim	 analysis	𝑗	the	 following	 test	 statistics	 are	
constructed	
	
𝑇!" 𝜎 = 𝑋!" − 𝑋!!𝜎 1𝑁!! + 1𝑁!" , 𝑘 = 1,… ,𝐾.	
	
When	 𝜎 	is	 assumed	 known,	 the	 𝑇!" 𝜎 	are	 together	 multivariate	 normal	
(henceforth,	 the	𝑧 -test	 statistics).	 With	𝜎 	replaced	 by	 its	 estimate	𝜎! ,	 the	 joint	
distribution	 of	 the	 resulting	𝑡-test	 statistics,	𝑇!" = 𝑇!" 𝜎! ,	 does	 not	 have	 a	 simple	
form.	It	is	this	that	makes	the	determination	of	stopping	boundaries	for	use	with	𝑡-
test	statistics	difficult.		
	
The	parameters	describing	a	MAMS	design	are	then	fully	specified	given	efficacy	and	
futility	 stopping	 boundaries	𝒆 = 𝑒!,… , 𝑒! ! ∈ ℝ! 	and	𝒇 = 𝑓!,… , 𝑓! ! ∈ ℝ! ,	 with	𝑒! = 𝑓!	to	ensure	the	trial	has	at	most	𝐽	stages.	
	
We	now	 consider	 two	 categories	 of	MAMS	design:	 one	 that	 terminates	 the	 entire	
trial	as	soon	as	any	null	hypothesis	is	rejected,	and	one	that	stops	recruitment	only	
to	 those	 arms	 for	 which	 the	 corresponding	 null	 hypothesis	 has	 been	 accepted	 or	
rejected.	These	two	types	of	design	have	been	referred	to	as	including	simultaneous	
and	separate	stopping	respectively	[8].	
	
To	 describe	 our	 design,	 we	 introduce	 the	 vectors	𝝍 = 𝜓!,… ,𝜓! ! 	and	𝝎 =𝜔!,… ,𝜔! !,	where	
	
• 𝜓! ∈ 0,1 ,	with	𝜓! = 1	if	𝐻!! 	is	rejected,	and	𝜓! = 0	otherwise;	
• 𝜔! ∈ 1,… , 𝐽 ,	with	𝜔! = 𝑗	if	𝑗	is	the	analysis	at	which	𝐻!! 	is	rejected,	accepted,	
or	the	whole	trial	is	stopped	and	no	decision	on	𝐻!! 	is	made.	
	
Our	MAMS	𝑡-test	is	then	defined	as	follows	
	
1. Set	𝝍 = 𝜓!,… ,𝜓! ! = 𝝎 = 𝜔!,… ,𝜔! ! = 0,… ,0 ! 	and	𝑗 = 1.	
2. Conduct	 stage	𝑗 	of	 the	 trial,	 allocating	𝑛 	patients	 to	 the	 control	 arm,	 and	𝑛	
patients	to	each	arm	𝑘	with	𝜔! = 0.	
3. Compute	the	𝑇!".	
4. For	𝑘 = 1,… ,𝐾	
4.1. If	𝑇!" ∈ 𝑓! , 𝑒! 	for	𝑙 = 0,… , 𝑗 − 1	(with	the	convention	𝑇!! ∈ 𝑓!, 𝑒! 	∀𝑘)	
4.1.1. If	𝑇!" ≥ 𝑒! 	reject	𝐻!! 	and	set	𝜓! = 1,	𝜔! = 𝑗;	
4.1.2. If	𝑇!" < 𝑓! 	accept	𝐻!! 	and	set	𝜔! = 𝑗;	
5. When	 using	 the	 simultaneous	 stopping	 rule,	 if	 𝕀 𝜓! = 1!!!! = 0 	and	𝕀 𝜔! = 0!!!! > 0,	 set	𝑗 = 𝑗 + 1	and	 return	 to	 2.	 Else	 stop	 the	 trial,	 and	 for	
each	𝑘 	with	𝜔! = 0 ,	 set	𝜔! = 𝑗 .	 When	 using	 the	 separate	 stopping	 rule,	 if	𝕀 𝜔! = 0!!!! > 0,	set	𝑗 = 𝑗 + 1	and	return	to	2.	Else	stop	the	trial.	
	
On	trial	completion,	𝝍	and	𝝎	then	conform	to	their	designations	above.	
	
We	would	like	to	ensure	that	the	FWER,	the	probability	of	rejecting	at	least	one	true	
null	 hypothesis,	 is	 controlled	 to	 some	 level	𝛼.	 There	 are	 several	 ways	 to	 define	
power	 in	 a	multi-arm	 setting.	 Here,	 as	 in	 [2]	we	 desire	 power	 of	 at	 least	1− 𝛽	to	
reject	𝐻!! 	when	𝜃! = 𝛿!	and	𝜃! = 𝛿!	for	𝑘 = 2,… ,𝐾.	 This	 is	 the	 so-called	pairwise	
power	for	𝐻!! 	(see,	e.g.,	[9]).	
	
To	this	end,	define	
	 Ξ!"# = 𝝎,𝝍 ∈ 1,… , 𝐽 !× 0,1 ! ∶  if 𝕀 𝜔! ≤ 𝑗 𝕀 𝜓! = 1!!!! ≥ 1 then 𝕀 𝜔! > 𝑗
!
!!! = 0 ∀𝑗 ,	Ξ!"# = 𝝎,𝝍 ∈ 1,… , 𝐽 !× 0,1 ! .	
	
Here	𝕀 𝑥 	is	the	indicator	function	on	event	𝑥.	Furthermore,	Ξ!"#	and	Ξ!"#	represent	
the	 set	 of	 possible	𝝎,𝝍	combinations	 when	 using	 the	 simultaneous	 and	 separate	
stopping	rules	respectively.	
	
Then,	for	Ξ ∈ {Ξ!"#,Ξ!"#} set	according	to	the	chosen	stopping	rule,	take	
	 Ξ!"# = 𝝎,𝝍 ∈ Ξ ∶  𝕀 𝜓! = 1!!!! > 0 , Ξ! = 𝝎,𝝍 ∈ Ξ ∶  𝕀 𝜓! = 1 = 1 . 
 
Here,	Ξ!"#	and	Ξ!	are	 respectively	 the	 subsets	 of	 the	Ξ	such	 that	 at	 least	 one	 null	
hypothesis,	or	𝐻!! ,	is	rejected.	
	
Denoting	the	probability	of	a	particular	 𝝎,𝝍 	combination	on	trial	completion	for	a	
given	 vector	 of	 treatment	 effects	𝜽 = 𝜃!,… ,𝜃! ! 	by	ℙ 𝝎,𝝍 | 𝜽 ,	 we	 specify	 our	
required	operating	characteristics	as	
	                                             𝛼!"#$ = ℙ 𝝎,𝝍 | 𝟎𝝎,𝝍 ∈!!"# ≤ 𝛼,                                      1 	1− 𝛽!"#$% = ℙ 𝝎,𝝍 | 𝜹𝝎,𝝍 ∈!! ≥ 1− 𝛽,   	
	
where	𝜹 = 𝛿!, 𝛿!,… , 𝛿! !.	
	
Additionally,	we	optimise	our	choices	of	𝑛,	𝒆,	and	𝒇.	In	theory,	this	could	be	achieved	
for	 almost	 any	 optimality	 criteria,	 with	 several	 sensible	 choices	 having	 been	
previously	proposed	 (see,	e.g.,	 [10]).	Here,	we	 focus	on	minimising	some	weighted	
combination	 of	 the	 expected	 sample	 sizes	 (ESSs)	 when	𝜽 = 𝟎	and	𝜽 = 𝜹,	 and	 the	
maximal	possible	 sample	 size;	 an	approach	 that	has	 in	 several	 trial	design	 settings	
proved	effective	[5,11].	Note	that	
	 ESS 𝜽 = 𝑛 max! 𝜔! + 𝜔!!!!! ℙ 𝝎,𝝍 | 𝜽𝝎,𝝍 ∈! .	
	
This	could	 therefore,	 following	 [12],	be	achieved	by	 identifying	 the	𝑛,	𝒆,	and	𝒇	that	
minimise	the	following	function	
	 𝑤!ESS 𝟎 + 𝑤!ESS 𝜹 + 𝑤!𝑛𝐽 𝐾 + 1+ 𝑃 𝕀 𝛼!"#$ > 𝛼 𝛼!"#$ − 𝛼𝛼 + 𝕀 𝛽!"#$% > 𝛽 𝛽!"#$% − 𝛽𝛽 .	
	
Here	𝑃 ∈ ℝ! 	is	 a	 penalty	 for	 designs	 with	 undesirable	 operating	 characteristics,	
taken	as	the	sample	size	required	by	a	corresponding	single-stage	design.		Moreover,	
the	𝑤! ∈ ℝ ∪ {0},	 for	𝑖 = 1,2,3,	 are	weights	 given	 towards	 the	desires	 to	minimise	
the	three	included	factors.	Note	that	previous	work	suggests	that	designs	that	place	
all	 of	 their	 weight	 on	 one	 of	 the	 three	 factors	 (e.g.,	𝑤! = 1,𝑤! = 𝑤! = 0),	 will	
perform	 particularly	 badly	 for	 other	 choices	 of	 the	 weights	 [5,11].	 It	 is	 therefore	
advisable	to	consider	a	range	of	options	for	the	weights,	and	also	to	take	𝑤! ≠ 0,	for	𝑖 = 1,2,3.	
	
Unfortunately,	the	complex	joint	distribution	of	the	𝑇!" 	prevents	us	from	calculating	
the	ℙ 𝝎,𝝍 | 𝜽 	required	 for	 this	 exactly.	 Instead,	 we	 use	 a	Monte	 Carlo	 method.		
We	 offer	 first	 a	 more	 practical	 description	 of	 how	 this	 works,	 before	 providing	 a	
formal	description	below.	
	
Suppose	as	an	example	that	𝐽 = 𝐾 = 2,	𝜇! = 𝜇! = 𝜇! = 0,	𝜎! = 1,	and	that	we	will	
use	the	simultaneous	stopping	rule.	For	any	choice	of	values	for	𝑛,	𝒆 = 𝑒!, 𝑒! !,	and	𝒇 = 𝑓!, 𝑓! ! 	(with	𝑒! = 𝑓!),	 we	 can	 simulate	 a	 trials	 outcome	 by	 generating	 data	
from	 each	 treatment	 arm	 in	 stage	 one,	 using	 the	 fact	 that	𝑋!!!  ~ 𝑁 0,1 	for		𝑘 = 0,1,2	and	𝑖 = 1,… ,𝑛.	 	 With	 this	 data,	 the	𝑇!! 	for	𝑘 = 1, 2	can	 be	 formed.	 If	𝑇!! ≥ 𝑒!	for	𝑘 = 1	or	 2,	 the	 trial	 terminates,	with	 a	 familywise	 error	 (FWE)	 having	
occurred.	 If	𝑇!! < 𝑓!	for	𝑘 = 1	and	 2,	 then	 the	 trial	 also	 terminates	 here,	 with	 no	
FWE	 having	 occurred.	 Otherwise	 the	 trial	 progresses	 to	 stage	 2,	 with	 recruitment	
continued	in	arm	0	and	the	arms	𝑘	with	𝑓! ≤ 𝑇!! < 𝑒!.	We	draw	data	for	stage	two	
in	 these	arms	again	using	 the	standard	normal	distribution,	and	 then	compute	 the	𝑇!! 	for	 those	𝑘	with	𝑓! ≤ 𝑇!! < 𝑒! .	 The	 trial	 now	 terminates,	 either	 with	 a	 FWE	
having	 been	 committed	 if	 for	 at	 least	 one	 of	 these	𝑘,	𝑇!! ≥ 𝑒!,	 or	without	 a	 FWE	
having	been	committed	otherwise.	The	FWER	can	then	be	estimated	for	this	design	
by	 repeating	 the	 above	 process	 many	 times,	 and	 counting	 the	 proportion	 of	
instances	 in	 which	 a	 null	 hypothesis	 is	 rejected.	 Similarly,	 one	 can	 estimate	 the	
power	under	 the	 LFC,	 or	 estimate	ESSs.	A	 global	 optimisation	 routine	 can	 then	be	
used	to	search	for	the	optimal	values	of	𝑛,	𝒆,	and	𝒇.	
Formally,	 we	 generate	 𝑅 = 100,000 	independent	 sets	 of	 responses	 for	 each	
treatment	 arm	 under	𝜽 = 𝟎	for	 some	 suitably	 large	 value	 of	𝑛.	 Subsets	 of	 these	
datasets	are	 then	used	 to	 form	the	 responses	 for	any	smaller	value	of	𝑛.	Next,	 for	
any	𝑛,	𝒆,	and	𝒇,	and	chosen	stopping	rule,	for	the	𝑟th	dataset,	the	trial	is	conducted	
as	 specified	 above.	 Importantly,	 the	 values	 of	𝝎 	and	𝝍 	on	 trial	 completion	 are	
determined,	and	denoted	𝝎! 	and	𝝍!.	An	approximation	to	𝛼!"#$	for	 this	design	 is	
then	
	 𝛼!"#$ = 1𝑅 𝕀 𝝎! ,𝝍! ∈ Ξ!"#!!!! .	
	
We	 can	 similarly	 compute	 approximations	𝛽!"#$% ,	ESS 𝟎 ,	 and	ESS 𝜹 	to	𝛽!"#$%	ESS 𝟎 ,	 and	ESS 𝜹 .	 Thus,	 to	 find	 the	 optimal	 design,	 we	minimise	 the	 following	
function	in	𝑛,	𝒆	and	𝒇	
	 𝑤!ESS 𝟎 + 𝑤!ESS 𝜹 + 𝑤!𝑛𝐽 𝐾 + 1+ 𝑃 𝕀 𝛼!"#$ > 𝛼 𝛼!"#$ − 𝛼𝛼 + 𝕀 𝛽!"#$% > 𝛽 𝛽!"#$% − 𝛽𝛽 .	
	
Note	 that	 the	 requirement	 to	generate	datasets	necessitates	𝑛	to	be	 treated	as	an	
integer.	Thus,	an	algorithm	that	can	simultaneously	search	over	the	discrete	𝑛,	and	
the	continuous	𝒆	and	𝒇	is	required.	We	achieve	this	using	CEoptim	in	R	[13].	Code	to	
implement	 our	 method	 is	 available	 from	
https://sites.google.com/site/jmswason/supplementary-material.	
	
3. Results	
	
We	 consider	 examples	 based	 on	 the	 TAILoR	 trial	 [2].	 The	 trial	 tested	 three	
experimental	 treatments.	We	 therefore	 take	𝐾 = 3,	 and	 as	 an	 example	 set	𝐽 = 2,	𝜎! = 1,	𝛼 = 0.05,	 and	𝛽 = 0.1.	 Conforming	 to	 our	 recommendations	 above,	 we	
additionally	 take	 𝑤! = 𝑤! = 𝑤! = 1/3 	(the	 ‘balanced-optimal	 design’).	 As	 in	
previous	 work,	 we	 consider	 two	 scenarios	 [6].	 For	 Scenario	 1	 we	 set	𝛿! = 0.545,	𝛿! = 0.178,	and	for	Scenario	2,	𝛿! = 1,	𝛿! = 0.	
	
For	 both	 scenarios,	 and	 both	 considered	 stopping	 rules,	 we	 determined	 the	
balanced-optimal	design	for	𝑡-test	statistics	using	the	Monte	Carlo	method	described	
above	 (denoting	 the	 optimal	 values	 by	𝑛! ,	𝒆! ,	𝒇! ).	 For	 comparison,	 we	 use	 the	
triangular	designs	[14]	for	𝑧-test	statistics	(denoting	the	values	by	𝑛!,	𝒆!,	𝒇!),	which	
can	be	found	using	the	MAMS	package	in	R	[2].	These	designs	are	so-named	for	the	
shape	 of	 their	 stopping	 regions,	 can	 be	 found	 quickly,	 and	 have	 been	 shown	 to	
provide	 good	 performance	 in	 terms	 of	 their	 associated	 ESSs	 for	MAMS	 trials	 [12].	
The	 resultant	 designs	 are	 given	 in	 Table	 1.	 Note	 that	 it	 is	 by	 construction	 of	 the	
triangular	test	that	the	boundaries	are	equal	 in	each	instance,	subject	to	numerical	
error.	
	
	
Scenario	
	
	 Stopping	rule	
Triangular	Design	 	 Balanced-Optimal	Design	𝑛! 	 𝒇! 	 𝒆! 	 	 𝑛! 	 𝒇! 	 𝒆! 	
Scenario	1	
Scenario	1	
Simultaneous	
Separate	
45	43	 0.777,2.197 ! 	0.777,2.198 ! 	 2.330,2.197 ! 	2.330,2.197 ! 	 	 41	40	 0.606,2.084 ! 	0.721,2.052 ! 	 2.742,2.084 ! 	2.925,2.052 ! 	
Scenario	2	 Simultaneous	 13	 0.777,2.197 ! 	 2.330,2.197 ! 	 	 12	 0.603,2.010 ! 	 2.942,2.010 ! 	
Scenario	2	 Separate	 13	 0.777,2.197 ! 	 2.330,2.197 ! 	 	 12	 0.668,2.086 ! 	 2.990,2.086 ! 	
Table	1:	The	triangular	designs	determined	using	the	known	variance	test	statistics,	
and	 the	 balanced-optimal	 designs	 determined	 using	 the	 unknown	 variance	 test	
statistics,	 are	displayed	 for	 the	 two	 considered	 trial	 design	 scenarios,	 and	 the	 two	
considered	stopping	rules.	All	boundaries	are	given	to	three	decimal	places.	
	
We	then	examined,	using	100,000	trial	simulations,	the	performance	of	the	following	
approaches	as	a	function	of	the	true	variance	𝜎!!	
	
A1. 𝑛!,	𝒆!,	𝒇!	with	𝑧-test	statistics	and	the	presumed	value	of	𝜎!;	
A2. 𝑛!,	𝒆!,	𝒇!	with	𝑡-test	statistics;	
A3. 𝑛! ,	𝒆! ,	𝒇! 	with	𝑡-test	 statistics,	 and	 modification	 of	 the	𝒆! ,	𝒇! 	using	 quantile	
substitution.	 That	 is,	 at	 interim	 analysis	 𝑗 	we	 replace	 𝑒!" 	and	 𝑓!" 	by	 𝑒!"! =𝑇 !!"!!!! ! !!! 1− 𝛷 𝑒!" 	and	𝑓!"! = 𝑇 !!"!!!! ! !!! 1− 𝛷 𝑓!" ,	 where	𝑇!	
is	 the	 cumulative	distribution	 function	of	 Student’s	𝑡-distibution	with	𝜈	degrees	
of	freedom;	
A4. 𝑛!,	𝒆!,	𝒇!	with	the	𝑡-test	statistics.	
	
The	results	of	these	comparisons	are	given	in	Table	2.	In	both	scenarios,	using	either	
stopping	 rule,	assumption	of	known	variance	 results	 in	 large	 inflation	of	 the	FWER	
when	𝜎!! > 𝜎!.	 In	 contrast,	 Approaches	 3	 and	 4	 far	 more	 accurately	 control	 the	
FWER	in	all	cases,	with	Approach	4	controlling	to	the	nominal	level	on	slightly	more	
occasions	 overall.	Moreover,	whilst	ESS 𝜹 	is	 comparable	 for	 Approaches	 3	 and	 4,	
Approach	4	always	attains	a	lower	value	for	ESS 𝟎 .	
	
4. Discussion	
	
In	this	article,	we	extended	previous	work	for	two-armed	group	sequential	trials	to	
allow	 the	 design	 parameters	 of	 a	 MAMS	𝑡-test	 to	 be	 optimised,	 when	 employing	
either	a	 simultaneous	or	 separate	 stopping	 rule.	 For	 the	 considered	examples,	 the	
method	was	successful	 in	providing	operating	characteristics	close	to	their	nominal	
level.	
	
It	is	important	to	note	that	by	Equation	(1),	the	FWER	is	controlled	under	the	global	
null	 hypothesis	 (𝜽 = 𝟎 ).	 This	 is	 known	 to	 provide	 strong	 control	 under	 the	
assumption	 of	 known	 variance	 with	𝑧-test	 statistics	 [2].	 However,	 it	 is	 not	 known	
whether	 this	 is	 the	 case	 for	 the	𝑡-test	 statistics	 considered	 here.	 Therefore,	whilst	
intuitively	 it	 seems	 logical	 that	 Equation	 (1)	 would	 provide	 strong	 control	 in	 this	
setting,	 a	 search	 over	 the	 vector	 𝜽 	should	 be	 employed	 after	 initial	 design	
determination	to	verify	this.	
	
In	 conclusion,	 our	 method	 provides	 an	 alternative	 approach	 for	 dealing	 with	
unknown	 variance	 to	 the	 heuristic	 quantile	 substitution	 procedure.	 Precisely,	
quantile	 substitution	offers	a	quick,	often	effective	means	of	 controlling	 the	FWER	
relatively	 accurately.	 However,	 if	 it	 is	 vital	 to	 control	 the	 FWER,	 the	 proposed	
method	should	be	preferable,	and	additionally	allows	the	stopping	boundaries	to	be	
optimised.	 In	 certain	 circumstances	 it	 can	 therefore	 be	 expected	 to	 allow	 the	
determination	of	more	efficient	designs.	
	
Factor	 Approach	
Scenario	1	 	 Scenario	2	𝜎!!	 	 𝜎!!	𝟎.𝟐𝟓	 𝟎.𝟓	 𝟏.𝟎	 𝟐.𝟎	 𝟒.𝟎	 	 𝟎.𝟐𝟓	 𝟎.𝟓	 𝟏.𝟎	 𝟐.𝟎	 𝟒.𝟎	
Simultaneous	stopping	rule	designs	
𝜶𝐅𝐖𝐄𝐑	 A1	 0.0000	 0.0035	 0.0499	 0.1816	 0.3421	 	 0.0000	 0.0035	 0.0495	 0.1820	 0.3450	A2	 0.0508	 0.0508	 0.0518	 0.0517	 0.0514	 	 0.0582	 0.0561	 0.0556	 0.0570	 0.0557	A3	 0.0491	 0.0492	 0.0501	 0.0497	 0.0496	 	 0.0519	 0.0497	 0.0500	 0.0503	 0.0495	
A4	 0.0493	 0.0490	 0.0504	 0.0504	 0.0487	 	 0.0510	 0.0487	 0.0495	 0.0494	 0.0489	
𝟏 − 𝜷𝐩𝐨𝐰𝐞𝐫	 A1	 0.9981	 0.9776	 0.9078	 0.7986	 0.6949	 	 0.9970	 0.9740	 0.9100	 0.8120	 0.7140	A2	 1.0000	 0.9952	 0.9080	 0.6314	 0.3541	 	 1.000	 0.9960	 0.9090	 0.6330	 0.3610	A3	 0.9999	 0.9951	 0.9068	 0.6276	 0.3498	 	 1.000	 0.9960	 0.9030	 0.6180	 0.3450	
A4	 0.9999	 0.9939	 0.9017	 0.6258	 0.3516	 	 1.000	 0.9960	 0.9010	 0.6210	 0.3530	
𝐄𝐒𝐒 𝟎 	 A1	 194.2	 210.6	 224.6	 225.3	 216.2	 	 56.2	 60.9	 64.8	 65.0	 62.6	A2	 223.8	 224.0	 224.4	 224.3	 224.0	 	 64.7	 64.7	 64.7	 64.6	 64.8	A3	 223.9	 224.1	 224.5	 224.4	 224.1	 	 64.8	 64.8	 64.8	 64.7	 64.9	
A4	 216.0	 216.1	 216.7	 216.3	 216.2	 	 63.6	 63.5	 63.5	 63.5	 63.6	
𝐄𝐒𝐒 𝜹 	 A1	 216.4	 222.1	 222.6	 217.6	 208.8	 	 60.6	 62.0	 62.6	 61.9	 60.2	A2	 180.3	 190.4	 222.5	 246.8	 252.0	 	 52.1	 54.7	 62.5	 68.3	 69.9	A3	 180.3	 190.9	 223.6	 247.8	 252.8	 	 52.1	 55.2	 63.4	 69.2	 70.5	
A4	 165.6	 190.5	 232.6	 251.3	 250.3	 	 48.7	 55.9	 66.4	 70.7	 70.6	
Separate	stopping	rule	designs	
𝜶𝐅𝐖𝐄𝐑	 A1	 0.0000	 0.0035	 0.0494	 0.1820	 0.3410	 	 0.0000	 0.0035	 0.0507	 0.1818	 0.3461	A2	 0.0509	 0.0519	 0.0519	 0.0517	 0.0522	 	 0.0569	 0.0561	 0.0567	 0.0575	 0.0568	A3	 0.0489	 0.0500	 0.0501	 0.0499	 0.0504	 	 0.0501	 0.0497	 0.0504	 0.0509	 0.0499	
A4	 0.0494	 0.0501	 0.0497	 0.0498	 0.0508	 	 0.0504	 0.0498	 0.0499	 0.0506	 0.0497	
𝟏 − 𝜷𝐩𝐨𝐰𝐞𝐫	 A1	 0.9970	 0.9720	 0.9060	 0.8110	 0.7260	 	 0.9975	 0.9747	 0.9096	 0.8168	 0.7292	A2	 1.0000	 0.9960	 0.9050	 0.6220	 0.3490	 	 1.0000	 0.9964	 0.9080	 0.6347	 0.3625	A3	 1.0000	 0.9960	 0.9040	 0.6170	 0.3440	 	 1.0000	 0.9960	 0.9020	 0.6183	 0.3462	
A4	 1.0000	 0.9950	 0.9000	 0.6220	 0.3520	 	 1.0000	 0.9953	 0.8992	 0.6215	 0.3536	
𝐄𝐒𝐒 𝟎 	 A1	 185.6	 201.2	 217.0	 224.1	 222.5	 	 56.1	 60.9	 65.5	 67.8	 67.3	A2	 216.6	 216.3	 217.0	 216.6	 216.7	 	 65.5	 65.4	 65.5	 65.5	 65.6	A3	 216.5	 216.3	 217.0	 216.6	 216.7	 	 65.5	 65.4	 65.5	 65.5	 65.6	
A4	 205.7	 205.6	 206.2	 205.7	 205.8	 	 62.7	 62.6	 62.7	 62.7	 62.8	
𝐄𝐒𝐒 𝜹 	 A1	 271.1	 270.4	 263.5	 250.0	 234.7	 	 63.4	 67.7	 70.7	 70.9	 68.8	A2	 253.5	 255.8	 263.3	 263.3	 255.3	 	 61.8	 64.2	 70.7	 73.9	 73.2	A3	 254.3	 256.6	 264.0	 263.9	 255.6	 	 61.8	 64.6	 71.4	 74.4	 73.4	
A4	 254.1	 257.9	 263.9	 257.9	 245.9	 	 59.4	 65.6	 72.1	 73.0	 71.0	
Table	 2:	 The	 estimated	 familywise	 error-rate	 (𝛼!"#$),	 power	 (1− 𝛽!"#$%),	 and	
expected	 sample	 sizes	 (ESSs)	when	𝜽 = 𝟎	(ESS 𝟎 )	 and	𝜽 = 𝜹	(ESS 𝜹 )	 of	 the	 four	
considered	approaches	(A1-A4)	are	shown	as	the	true	variance	𝜎!!	varies,	for	the	two	
considered	 trial	 design	 scenarios,	 and	 the	 two	 considered	 stopping	 rules.	 The	
rejection	rate	and	ESS	values	are	given	to	four	and	one	decimal	places	respectively.	
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